p53 mutation is associated with high S-phase fraction in primary fallopian tube adenocarcinoma

British Journal of Cancer

Volumn 74, Issue 8, 1996, Pages 1157-1160

  Runnebaum, I B ^a   Kohler T ^a   Stickeler, E ^a   Rosenthal, H E ^a   Kieback, D G ^a   Kreienberg, R ^a  

^a UNIVERSITY OF ULM   (Germany)

Author keywords

Cell cycle; Fallopian tube cancer; Human papilloma virus (HPV); p53 mutation

Indexed keywords

MUTANT PROTEIN; PROTEIN P53;

ADENOCARCINOMA; ARTICLE; CANCER GRADING; CELL CYCLE S PHASE; CLINICAL ARTICLE; CODON; FEMALE; FRAMESHIFT MUTATION; GENE MUTATION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MISSENSE MUTATION; NUCLEOTIDE SEQUENCE; POINT MUTATION; PRIORITY JOURNAL; UTERINE TUBE; UTERINE TUBE CARCINOMA; WART VIRUS;

EID: 0029801517     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1996.510     Document Type: Article

References (39)

1. BAKER SJ, MARKOWITZ S, FEARON ER, WILLSON JK AND VOGELSTEIN B. (1990). Suppression of human colorectal carcinoma cell growth by wild-type p53. Science, 249, 912 - 915.
2. CHEN J, JACKSON PK, KIRSCHNER MW AND DUTTA A. (1995). Separate domains of p21 involved in the inhibition of Cdk kinase and PCNA. Nature, 374, 386 - 388.
3. CHENG J, YEE JK, YEARGIN J, FRIEDMANN T AND HAAS M (1992). Suppression of acute lymphoblastic leukemia by the human wild-type p53 gene. Cancer Res., 52, 222 - 226.
4. CHO Y, GORINA S, JEFFREY PD AND PAVLETICH NP. (1994). Crystal structure of a p53 tumor suppressor-DNA complex: Understanding tumorigenic mutations. Science, 265, 346 - 355.
5. CLORE GM, OMICHINSKI JG, SAKAGUCHI K, ZAMBRANO N, SAKAMOTO H, APPELLA E AND GRONENBORN AM. (1994). High-resolution structure of the oligomerization domain of p53 by multidimensional NMR. Science, 265, 386 - 391.
6. EDDY GL, COPELAND LJ, GERSHENSON DM, ATKINSON EN, WHARTON JT AND RUTLEDGE FN. (1984). Fallopian tube cacinoma. Obstet. Gynecol., 64, 546 - 552.
7. EL-DEIRY WS, TAKINO T. VELCULESCI VE, LEVY DB, PARSON R, TRENT JM, LIN D, MERCER WE, KINZLER KW AND VOGELSTEIN B. (1993). WAF1, a potential mediator of p53 tumor suppression. Cell, 75, 817 - 825.
8. HLIYAHU D, MICHALOVITZ D, HLIYAHU S, PINHASI KO AND OREN M. (1989). Wild-type p53 can inhibit oncogene-mediated focus formation. Proc. Natl Acad. Sci. USA, 86, 8763 - 8767.
9. HARPER JW, ADAMI GR, WEI N, KEYOMARSI K AND ELLEDGK SJ. (1993). The p21 cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell, 75, 805 - 816.
10. KASTAN MB, ONYEKWERE O, SIDRANSKY D, VOGELSTHIN BAND CRAIG RW. (1991). Participation of p53 protein in the cellular response to DNA damage. Cancer Res., 51, 6304 - 6311.
11. KASTAN MB, ZHAN Q, EL-DEIRY WS, CARRIER F, JACKS T, WALSH WV, PLUNKETT BS, VOGELSTEIN B AND FORNACE AJJ. (1992). A mammalian cell cycle checkpoint pathway utilzing p53 and GADD45 is defective in ataxia-telangiectasia. Cell, 71, 587 - 597.
12. KERN SE, KINZLER KW, BRUSKIN A, JAROSZ D, FRIEDMAN P, PRIVES C AND VOGELSEIN B. (1991). Identification of p53 as a sequence-specific DNA-binding protein. Science, 252, 1708 - 1711.
13. KIEBACK DG, PRESS MF, ATKINSON EN, MÖBUS VJ, RUNNEBAUM IB, KREIENBERG R AND JONES LA. (1993). Prognostic significance of estrogen receptor expression in ovarian cancer. Immunoreactive score (IRS) vs. composition adjusted receptor level (CARL). Anticancer Res., 13, 2489 - 2496.
14. KUPRYJANCZYK J, THOR AD. BEAUCHAMP R, MERRITT V, EDGERTON SM, BELL DA AND YANDELL DW. (1993). p53 gene mutations and protein accumulation in human ovarian cancer. Proc. Natl Acad. Sci. USA, 90, 4961 - 4965.
15. LACY MQ, HARTMANN LC, KEENEY GL, CHA SC, WIEAND HS, PODRATZ KC AND ROCHE PC. (1995). c-erbB-2 and p53 expression in fallopian tube carcinoma. Cancer, 75, 2891 - 2896.
16. LOWE SW AND RULEY HE, (1993). Stabilization of the p53 tumor suppressor is induced by adenovirus 5 FIA and accompanies apoptosis, Genes Dev., 7, 535 - 545.
17. LUO Y, HURWITZ J AND MASSAGUE J. (1995), Cell-cycle inhibition by independent CDK and PCNA binding domains in p21Cip1. Nature, 375, 159 - 161.
18. MARKS JR, DAVIDOFF AM, KERNS BJ, HUMPHREY PA, PENCE JC, DODGE RK, CLARKE-PEARSON D, IGLLHART JD. BAST RCJ AND BERCHUCK A. (1991). Overexpression and mutation of p53 in epithelial ovarian cancer. Cancer Res., 51, 2979 - 2984.
19. MILNER BJ, ALLAN LA, ECCLES DM, KITCHENER HC, LEONARD RCF, KELLY KF, PARKIN DE AND HAITES NE. (1993). p53 Mutation is a common genetic event in ovarian carcinoma. Cancer Res., 53, 2128 - 2132.
20. MIYASHITA T, KRAJEWSKI S, KRAJEWSKA M, WANG HG, LIN HK, LIEBERMANN DA, HOFFMAN B AND REED JC. (1994). Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo. Oncogene, 9, 1799 - 1805.
21. MIYASHITA T AND REED JC. (1995). Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell, 80, 293 - 299.
22. NORDIN AJ. (1994). Primary carcinoma of the fallopian tube: a 20-year literature review. Obstet. Gynecol. Surv., 49, 349 - 361.
23. OKAMOTO A, SAMESHIMA Y, YOKOYAMA S, TERASHIMA Y, SUGIMURA T, TERADA M AND YOKOTA J. (1991). Frequent allclic losses and mutations of the p53 gene in human ovarian cancer. Cancer Res., 51, 5171-5176.
24. REMMELE W AND STEGNER HE. (1987). Vorschlag zur einheitlichen Definition eines Immunreaktiven Score (IRS) für den immunhistochemischen Östrogenrezeptor-Nachweis. Pathologe, 8, 138 - 140.
25. ROSE PG, PIVER MS AND TSUKADA Y. (1990). Fallopian tube cancer. The Roswell Park experience. Cancer, 66, 2661 - 2667.
26. ROSEN A. KLEIN M, LAHOUSEN M, GRAF AH, RAINER A AND VAVRA N. (1993). Primary carcinoma of the fallopian tube a retrospective analysis of 115 patients. Austrian Cooperative Study Group for Fallopian Tube Carcinoma. Br. J. Cancer, 68, 605 - 609.
27. RUNNEBAUM IB AND KREIENBERG R. (1995). p53 transdominantly suppresses tumor formation of human breast cancer cells mediated by retroviral bulk infection without marker gene selection: an expeditious in vitro protocol with implications towards gene therapy. Hybridoma, 14, 153 - 157.
28. RUNNEBAUM IB, NAGARAJAN M, BOWMAN M, SOTO D AND SUKUMAR S. (1991). Mutations in p53 as potential molecular markers for human breast cancer. Proc. Natl Acad. Sci. USA, 88, 10657 - 10661.
29. RUNNEBAUM IB, TONG X-W, MOEBUS V, HEILMANN V, KIEBACK DG AND KREIENBERG R. (1994a). Multiplex PCR (MPCR) screening detects small p53 deletions and insertions in human ovarian cancer cell lines. Hum. Genet., 93, 620 - 624.
30. RUNNEBAUM IB, TONG XW, MÖBUS VJ, KIEBACK DG, ROSENTHAL HE AND KREIENBERG R. (1994b). p53 mutant His175 identified in a newly established fallopian tube carcinoma cell line secreting interleukin 6. FEBS Lett., 353, 29 - 32.
31. RUNNEBAUM IB, YEE J-K, KIEBACK DG, SUKUMAR S AND FRIEDMANN T. (1994c). Wild-type p53 suppresses the malignant phenotype in breast cancer cells containing mutant p53 alleles. Anticancer Res., 14, 1137 - 1144.
32. RUNNEBAUM IB, TONG XW, KÖNIG R, HONG Z, KÖRNER K, ATKINSON EN, KREIENBERG R AND KIEBACK DG. (1995a). p53-based blood test for p53PIN3 and risk for sporadic ovarian cancer. Lancet, 345, 994.
33. RUNNEBAUM IB, WANG S AND KREIENBERG R. (1995b). Retrovirally mediated wild-type p53 restores S phase modulation without inducing W AF1 mRNA in breast carcinoma cells containing mutant p53. J. Cell. Bioehem., 59, 538 - 544.
34. RUNNEBAUM IB, MAIER S, TONG XW, ROSENTHAL HE, MÖBUS VJ, KIEBACK DG AND KREIENBERG R. (1995c). Human papillomavirus integration is not associated with advanced epithelial ovarian cancer in German patients. Cancer Epidemiol. Biomarkers, 4, 573 - 575.
35. RUNNEBAUM IB, KIEBACK DG, MÖBUS VJ, TONG X-W AND KREIENBERG R. (1996). Subcellular localization of accumulated p53 in ovarian cancer cells. Gynecol. Oncol., 61, 266 - 271.
36. SCHEFFNER M, WERNESS BA, HUIBREGTSK JM, LEVINE AJ AND HOWLEY PM. (1990). The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell. 63, 1129 - 1136.
37. TSAO SW, MOK CH, OIEK K, MUTO M, GOODMAN HM, SHEETS EE, BERKOWITZ RS, KNAPP RC AND LAU CC. (1991). Involvement of p53 gene in the allelic deletion of chromosome 17p in human ovarian tumors. Anticancer Res., 11, 1975 - 1982.
38. UNGER T, NAU MM, SEGAL S AND MINNA JD. (1992). p53: a transdominant regulator of transcription whose function is ablated by mutations occurring in human cancer. Embo J., 11, 1383 - 1390.
39. YONISH-ROUACH E, GRUNWALD D, WILDER S, KIMCHI A, MAY E, LAWRENCE J-J, MAY P AND OREN M. (1993). p53-mediated cell death: relationship to cell cycle control. Mol. Cell. Biol., 13, 1415 - 1423.